RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19

This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) titled, "NextGen Oral Formulation Vaccines for COVID-19".

The purpose of this effort is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, improve our understanding of their potential, and to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. The full RPP and information on joining the consortium can be accessed through the RRPV website at www.rrpv.org. Amended to extend the due date from 18 October 2024 to 1 November 2024. Amended to extend the due date from 1 November 2024 to 15 November 2024.